➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Johnson and Johnson
Mallinckrodt
AstraZeneca
Harvard Business School

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XPOVIO

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Xpovio

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04349098 Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection Not yet recruiting Karyopharm Therapeutics Inc Phase 2 2020-04-30 The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in patients with severe COVID-19 compared to placebo.
NCT04355676 Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 Not yet recruiting Karyopharm Therapeutics Inc Phase 2 2020-04-30 The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.
NCT04414475 A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma Not yet recruiting Karyopharm Therapeutics Inc Phase 2 2020-06-30 The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xpovio

Condition Name

Condition Name for Xpovio
Intervention Trials
Recurrent Plasma Cell Myeloma 2
Coronavirus Infection 2
Refractory Plasma Cell Myeloma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xpovio
Intervention Trials
Multiple Myeloma 5
Neoplasms, Plasma Cell 5
Severe Acute Respiratory Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xpovio

Trials by Country

Trials by Country for Xpovio
Location Trials
United States 11
Norway 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xpovio
Location Trials
Minnesota 3
Colorado 1
Wisconsin 1
Pennsylvania 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xpovio

Clinical Trial Phase

Clinical Trial Phase for Xpovio
Clinical Trial Phase Trials
Phase 2 6
Phase 1/Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xpovio
Clinical Trial Phase Trials
Not yet recruiting 8
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xpovio

Sponsor Name

Sponsor Name for Xpovio
Sponsor Trials
Karyopharm Therapeutics Inc 6
National Cancer Institute (NCI) 3
Mayo Clinic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xpovio
Sponsor Trials
Industry 7
Other 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Mallinckrodt
Baxter
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.